Figure 6. ELR510444 reduces tumor burden and cell proliferation and stimulates apoptosis.

(A) 786-O and A498 cells (1×10⁷/mouse) were injected into the flanks of nude mice. When tumors reached approximately 150 mm³ in size, mice were randomized into groups and treated on a QDx5 schedule with 8 mg/kg ELR510444 for 2 weeks. Tumor volume was measured twice weekly. Mean ± SEM, n = 10. *Indicates a significant difference compared to vehicle, p<0.05. (B) ELR510444 was well tolerated in vivo. Animal body weight was measured throughout the study to quantify drug-induced weight loss. Mean ± SD, n = 10. (C) ELR510444 reduces tumor cell proliferation. PCNA levels were determined by conducting immunohistochemistry on tumor sections. Positive cells were scored manually. Mean ± SD, n = 5. *Indicates a significant difference compared to controls (vehicle), p<0.05. (D) ELR510444 induces apoptosis. Apoptosis was measured by cleaved caspase-3 staining. Quantification was conducted by manually counting positive cells. Mean ± SD, n = 5. *Indicates a significant difference compared to controls (vehicle), p<0.05.